The latest FDA drug approval is vepdegestrant, a heterobifunctional protein degrader, for ESR1 mutated breast cancer. We discuss what that actually means and some possible implications for clinical practice.
Check out the Oncology Insights Newsletter: www.kelleycpharmd.com/newsletter-oncopharm
